Sunitinib for advanced renal cell cancer

References

• AbramsTJLeeLBMurrayLJ2003SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancerMol Cancer Ther247147812748309
   PubMed Web of Science ®Google Scholar
• *AmatoRJHarrisPDaltonM2007A phase II trial of intra-patient dose-escalated sorafenib in patients with metastatic renal cell cancerJ Clin Oncol2518S ASCO Proc:5026
   Google Scholar
• AtkinsMB2007Molecularly targeted therapy for advanced renal cell carcinomaUpToDate^® [online]Accessed 15 Aug 2007 URL: www.uptodate.com
   Google Scholar
• BelloCLGarrettMSmergliaJ2006Pharmacokinetics of sunitinib malate (SU11248) in subjects with hepatic impairmentAnnals Oncol17S9 ESMO Proc:451P
   Google Scholar
• ChowLQMEckhardtSG2007Sunitinib: from rational design to clinical efficacyJ Clin Oncol258849617327610
   PubMed Web of Science ®Google Scholar
• ChowdhurySSpicerJEHarperPG2006Hypertension and targeted therapy. Part 2: small molecule inhibitors of VEGFTargeted Oncol11728
   Web of Science ®Google Scholar
• CoppinCPorzsoltFAutenriethM2004Immunotherapy for advanced renal cell cancer (review)Cochrane Database of Systematic Reviews 20042Wiley
   Google Scholar
• CoppinCLeLPorzoltF2008Targeted therapy for advanced renal cell carcinoma (review)Cochrane Database of Systematic Reviews 20082In press
   Google Scholar
• DemetriGDvan OosteromATGarrettCR2006Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trialLancet3681329133817046465
   PubMed Web of Science ®Google Scholar
• DesaiJYassaLMarquseeEGeorgeS2006Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumorsAnn Intern Med145660417088579
   PubMed Web of Science ®Google Scholar
• *DutcherJPSzczylikCTannirN2007Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alphaJ Clin Oncol2518S ASCO Proc:5033
   Google Scholar
• EddyDM1994Principles for making difficult decisions in difficult timesJAMA271179288196126
   PubMed Web of Science ®Google Scholar
• ElarajDMWhiteDESteinbergSM2004A pilot study of antiangiogeneic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinomaJ Immunother272596415235386
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWM2007aSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med3561253417215530
   PubMed Web of Science ®Google Scholar
• *EscudierBKoralewskiPPluzanskaA2007bA randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinomaJ Clin Oncol2518S ASCO Proc:3
   PubMedGoogle Scholar
• FaivreSDelbaldoCVeraK2006Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancerJ Clin Oncol24253516314617
   PubMed Web of Science ®Google Scholar
• FyfeGAFisherRIRosenbergSA1996Long term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapyJ Clin Oncol1424108708739
   PubMed Web of Science ®Google Scholar
• GarberK2003Sugen falls as casualty of Pfizer-Pharmacia mergerNat Biotechnol21722312833079
   PubMed Web of Science ®Google Scholar
• *GeorgeDJMichaelsonMDRosenbergJE2007Phse II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma: updated results and analysis of circulating biomarkersJ Clin Oncol2518S ASCO Proc:5035
   Google Scholar
• GleaveMEElhilaliMFradetY1998Interferon gamma-1b compared with placebo in metastatic renal-cell carcinomaN Engl J Med3381265719562580
   PubMed Web of Science ®Google Scholar
• GoffinJBaralSTuD2005Objective responses in patients with malignant melanoma or renal cell cancer in early studies do not predict regulatory approvalClin Cancer Res1159283416115935
   PubMed Web of Science ®Google Scholar
• GoodmanVLRockEPDagherR2007Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinomaClin Cancer Res1313677317332278
   PubMed Web of Science ®Google Scholar
• *GordonMSManolaJFaircloughD2004Low dose interferon-a2b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A phase III study of the Eastern Cooperative Oncology Group (E2898)J Clin Oncol2214S ASCO Proc:4516
   Google Scholar
• GoreMEPortaCOudardS2007Sunitinib in metastatic renal cell carcinoma: preliminary assessment of toxicity in an expanded access trial with subpopulation analysisJ Clin Oncol2518S ASCO Proc:5010
   Google Scholar
• HanaganDWeinbergRA2000The hallmarks of cancerCell100577010647931
   PubMed Web of Science ®Google Scholar
• *HoukBEBelloCLMichaelsonMD2007Exposure-response of sunitinib in metastatic renal cell carcinoma: a population pharmacokinetic/pharmacodynamic approachJ Clin Oncol2518S ASCO Proc:15572
   Google Scholar
• HudesGCarducciMTomczakP2007Temsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med35622718117538086
   PubMed Web of Science ®Google Scholar
• KerbelRFolkmanJ2002Clinical translation of angiogenesis inhibitorsNat Rev Cancer27273912360276
   PubMed Web of Science ®Google Scholar
• KollmannsbergerCKHengDYMurrayN2007A population-based study evaluating metastatic renal cell cancer patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib aloneJ Clin Oncol2518S ASCO Proc:15572
   PubMedGoogle Scholar
• LinehanWMGrubbRLColemanJA2005The genetic basis of kidney cancer: implications for gene-specific clinical managementBJU Int95S22715720328
   PubMed Web of Science ®Google Scholar
• ManningGWhyteDBMartinezR2002The protein kinase complement of the human genomeScience29819123412471243
   PubMed Web of Science ®Google Scholar
• McDermottDFReganMMClarkJI2005Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaJ Clin Oncol231334115625368
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinX2003In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res93273712538485
   PubMed Web of Science ®Google Scholar
• MickischGHJ2003Rational selection of a control arm for randomized trials in metastatic renal cell carcinomaEur Urol43670912767369
   PubMed Web of Science ®Google Scholar
• MossKGTonerGCCherringtonJM2003Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humansJ Pharmacol Exp Ther30747648012966161
   PubMed Web of Science ®Google Scholar
• MRC Renal Cancer Collaborators1999Interferon-alpha and survival in metastatic renal cell carcinoma: early results of a randomized controlled trialLancet353141710023944
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBA2002Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol202899611773181
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJSchwartzLH2004Prognostic factors for survival in previously treated patients with metastatic renal cell carcinomaJ Clin Oncol2245446314752067
   PubMed Web of Science ®Google Scholar
• MotzerRJMichaelsonDRedmanBG2006aActivity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJ Clin Oncol24162416330672
   PubMed Web of Science ®Google Scholar
• MotzerRJRiniBIBukowskiRM2006bSunitinib in patients with metastatic renal cell carcinomaJAMA29525162416757724
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakP2007aSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med3561152417215529
   PubMed Web of Science ®Google Scholar
• *MotzerRJFiglinRAHutsonTE2007bSunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factorsJ Clin Oncol2518S ASCO Proc:5024
   Google Scholar
• NaXWuGRyanCK2003Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomasJ Urol1705889212853836
   PubMed Web of Science ®Google Scholar
• *NegrierSPerolDRavaudA2005Do cytokines improve survival in patients with metastatic ernal cell carcinoma of intermediate prognosis? Results of the prospectively randomized PERCY Quattro trialJ Clin Oncol2316S ASCO Proc:4511
   Google Scholar
• OliverRTDNethersellABWBottomleyJM1989Unexplained spontaneous regression and alpha-inerferon as treatment for metastatic renal carcinomaBr J Urol63128312702395
   PubMedGoogle Scholar
• OsuskyKLHallahanDEFuA2004The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vesselsAngiogenesis72253315609077
   PubMedGoogle Scholar
• PyrhonenSSalminenERuutuM1999Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancerJ Clin Oncol1728596710561363
   PubMed Web of Science ®Google Scholar
• RatainMJEckhardtSG2004Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECISTJ Clin Oncol224442515483011
   PubMed Web of Science ®Google Scholar
• RatainMJEisenTStadlerWM2006Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaJ Clin Oncol2425051216636341
   PubMed Web of Science ®Google Scholar
• *RemakEMullinsCDAkobunduE2007Economic evaluations of sunitinib versus interferon-alfa in first-line metastatic renal cell carcinomaJ Clin Oncol2518S ASCO Proc:6607
   Google Scholar
• RiniBISmallEJ2005Biology and clinical dvelopment of vascular endothelial growth factor-targeted therapy in renal cell carcinomaJ Clin Oncol231028104315534359
   PubMed Web of Science ®Google Scholar
• RiniBICampbellSC2007The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapyJ Urol17719788417509276
   PubMed Web of Science ®Google Scholar
• *SrinivasSRoigasJGillessenS2007Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma: updated resultsJ Clin Oncol2518S ASCO Proc:5040
   PubMedGoogle Scholar
• StadlerW2007aChromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug developmentClin Cancer Res131630317363513
   PubMed Web of Science ®Google Scholar
• StadlerWM2007bThe randomized discontinuation trial: a phase II design to assess growth-inhibitory agentsMol Cancer Ther61180517431101
   PubMed Web of Science ®Google Scholar
• SunLLiangCShirazianS2003Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinaseJ Med Chem4611161912646019
   PubMed Web of Science ®Google Scholar
• *SzczylikCDemkowTStaehlerM2007Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final resultsJ Clin Oncol2518S ASCO Proc:5025
   Google Scholar
• TherassePArbuckSGEisenhauerEA2000New guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst922051610655437
   PubMed Web of Science ®Google Scholar
• VogelzangNJSternbergCN2007Signal-transduction inhibitors in renal cell carcinomaBJU Int9912899517441926
   PubMed Web of Science ®Google Scholar
• WrightJCWeinsteinMC1998Gains in life expectancy from medical interventions - standardizing data on outcomesN Engl J Med33938069691106
   PubMed Web of Science ®Google Scholar
• ZiaMISiuLLPondGR2005Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimensJ Clin Oncol2369829116192585
   PubMed Web of Science ®Google Scholar